scholarly journals Current and Future Biological Treatments in Inflammatory Bowel Disease

10.5772/22333 ◽  
2011 ◽  
Author(s):  
Jesus K.
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Biological Treatments ◽  
Inflammatory Bowel

scholarly journals Biological Treatments in Inflammatory Bowel Disease: A Complex Mix of Mechanisms and Actions

Biologics ◽  
2021 ◽  
Vol 1 (2) ◽  
pp. 189-210
Author(s):  
Lorena Ortega Moreno ◽  
Samuel Fernández-Tomé ◽  
Raquel Abalo
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Treatment Guidelines ◽  
Efficacy And Safety ◽  
Pharmacological Treatments ◽  
Action Mechanism ◽  
Biological Treatments ◽  
Inflammatory Bowel ◽  
New Treatment

Inflammatory bowel disease (IBD) is a chronic disease that requires lifelong medication and whose incidence is increasing over the world. There is currently no cure for IBD, and the current therapeutic objective is to control the inflammatory process. Approximately one third of treated patients do not respond to treatment and refractoriness to treatment is common. Therefore, pharmacological treatments, such as monoclonal antibodies, are urgently needed, and new treatment guidelines are regularly published. Due to the extremely important current role of biologics in the therapy of IBD, herein we have briefly reviewed the main biological treatments currently available. In addition, we have focused on the mechanisms of action of the most relevant groups of biological agents in IBD therapy, which are not completely clear but are undoubtfully important for understanding both their therapeutic efficacy and the adverse side effects they may have. Further studies are necessary to better understand the action mechanism of these drugs, which will in turn help us to understand how to improve their efficacy and safety. These studies will hopefully pave the path for a personalized medicine.

Discontinuation of Biological Treatments in Inflammatory Bowel Disease

2018 ◽  
Vol 52 (1) ◽  
pp. 6-12 ◽  
Author(s):  
Shomron Ben-Horin ◽  
Ren Mao ◽  
Yun Qiu ◽  
Minhu Chen
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Biological Treatments ◽  
Inflammatory Bowel

Disease severity predicts bone loss: A longitudinal study in inflammatory bowel disease patients

2001 ◽  
Vol 120 (5) ◽  
pp. A628-A628
Author(s):  
S HENDERSON ◽  
S DHALIWAL ◽  
N HOFFMAN ◽  
R PRINCE
Keyword(s):  
Inflammatory Bowel Disease ◽  
Longitudinal Study ◽  
Bone Loss ◽  
Disease Severity ◽  
Bowel Disease ◽  
Inflammatory Bowel

Low bone mineral density in association with increased bone resorbtion in patient with inflammatory bowel disease at diagnosis

2001 ◽  
Vol 120 (5) ◽  
pp. A628-A628
Author(s):  
T WONG ◽  
D SMITH ◽  
D SIMPSON ◽  
A COAKLEY ◽  
C MONIZ ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Inflammatory Bowel Disease ◽  
Bone Mineral ◽  
Bowel Disease ◽  
Mineral Density ◽  
Low Bone Mineral Density ◽  
Inflammatory Bowel

6-Mercaptopurine metaboline profile is optimized by azathioprine formulation and non-use of 5-aminosalicylic acid angents in patients with inflammatory bowel disease

2001 ◽  
Vol 120 (5) ◽  
pp. A625-A625 ◽  
Author(s):  
T STEVENS ◽  
J ACHKAR ◽  
A BRZEZINSKI ◽  
D SEIDNER ◽  
B LASHNER
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Aminosalicylic Acid ◽  
Inflammatory Bowel

p53, MIB-1, BAX and BCL-2 expression in anal transitional zone (ATZ) dysplasia following ileo-pouch anal anastomosis (IPAA) for inflammatory bowel disease (IBD)

2001 ◽  
Vol 120 (5) ◽  
pp. A268-A268
Author(s):  
A ORMSBY ◽  
R PETRAS ◽  
T GRAMLICH ◽  
V FAZIO ◽  
F REMZI ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Transitional Zone ◽  
Anal Transitional Zone ◽  
Anal Anastomosis ◽  
Inflammatory Bowel ◽  
Mib 1
Sign in / Sign up

Export Citation Format

Share Document